Mid-cap Health Care company Apellis Pharmaceuticals has moved 0.7% so far today on a volume of 1,174,259, compared to its average of 4,590,561. In contrast, the S&P 500 index moved -0.0%.
Apellis Pharmaceuticals trades -37.25% away from its average analyst target price of $64.29 per share. The 14 analysts following the stock have set target prices ranging from $29.0 to $95.0, and on average have given Apellis Pharmaceuticals a rating of buy.
Anyone interested in buying APLS should be aware of the facts below:
-
Apellis Pharmaceuticals has moved -32.0% over the last year, and the S&P 500 logged a change of 7.0%
-
Based on its trailing earnings per share of -5.86, Apellis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -6.9 while the S&P 500 average is None
-
APLS has a forward P/E ratio of -10.9 based on its forward 12 month price to earnings (EPS) of $-3.7 per share
-
The company has a price to earnings growth (PEG) ratio of -0.24 — a number near or below 1 signifying that Apellis Pharmaceuticals is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 13.73 compared to its sector average of None
-
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
-
Based in Waltham, the company has 767 full time employees and a market cap of $4.86 Billion.